ESMO:阿斯利康(AstraZeneca)展示癌症药物布局
STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase
在ESMO会议上,阿斯利康(AstraZeneca)有4项药物研究入选总统演讲,展示了其癌症药物管线的广度。阿斯利康癌症研发负责人Susan Galbraith表示,这反映了其组合策略的灵活性及数据的深度与质量。
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
MADRID — For AstraZeneca, a major oncology conference here this weekend has been a sign of how the company’s cancer work is steamrolling ahead, with highlights from a mix of old standbys and new molecules that could expand its armament of medicines even further.
Four of the 12 presentations slotted in the presidential sessions at this year’s European Society for Medical Oncology’s congress featured AZ medicines. The meeting captured just how wide-ranging the company’s cancer work is, showing the power of new combinations of approved drugs and putting a spotlight on what could be the company’s next targeted chemotherapy to reach the market.
“That does speak to the breadth of the portfolio, but also the depth and quality of the data that we’re presenting,” Susan Galbraith, the head of AZ’s cancer R&D, told STAT.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com